Anika Therapeutics (ANIK) Receivables - Other (2023)
Anika Therapeutics (ANIK) posted quarterly Receivables - Other of $3.2 million for Q1 2023.
Anika Therapeutics (ANIK) Receivables - Other (2023) Analysis & Trends
Anika Therapeutics (ANIK) has reported Receivables - Other for 1 consecutive years, with $3.2 million the latest figure, recorded in Q1 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 43.98 Bn | 43.02 Bn | - |
| 2 | Teva Pharmaceutical Industries | 43.28 Bn | 39.62 Bn | 2.15 Bn |
| 3 | Zoetis | 31.79 Bn | 30.11 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.69 Bn | 22.89 Bn | 5.10 Bn |
| 5 | United Therapeutics | 22.25 Bn | 19.58 Bn | 683.80 Mn |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.58 Bn | 15.19 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 11.87 Bn | 11.34 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - |
| 10 | Anika Therapeutics | 285.26 Mn | 246.85 Mn | 21.24 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2023 | 3.25 Mn |
| Mar 31, 2023 | 3.25 Mn |